Mike Hollan

Key points from our recent webinar on the President’s MFN order.

The President plans to sign an executive order on Monday morning to enforce the trade clause.

The two company’s will provide consumers with a platform where they can compare drug prices.

Bruce Phelan of Blue Fin discusses Novo Nordisk's purchase of Catalent manufacturing sites to increase its ability to meet the demand for the popular weight loss drug Wegovy.

The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.

Technavio analysis notes that an increase drug patent expirations could be a contributing factor.

The deal is expected to help boost supply of Wegovy.

Kirsch discusses the complexity of the drugs and the verification process, along with Eversana’s new platform, ACTICS eAccess.